Breast cancer PAM50 subtypes
PAM50 stands for
Prediction Analysis of Microarray 50. It tests a sample of the tumor (removed during a biopsy or surgery) for a group of 50 genes. Along with other factors, the results of the PAM50 test help predict the chance of metastasis (when cancer spreads to other organs). It was proposed by Parker et al. in 2009.
The PAM50 is a RT-qPCR assay that measures the expression of 50 classifier genes and five control genes to identify the intrinsic subtypes known as Luminal A, Luminal B, HER2-enriched and Basal-like. Along with a categorical classification of breast cancer subtype, it also provides quantitative values for proliferation, luminal gene expression, ESR1, PGR and ERBB2.
Gene expression profiling by microarray has given us insight into the complexity of breast tumors and can be used to provide prognostic information beyond standard clinical assessment.
- the 21-gene OncotypeDx assay (Genome Health Inc, Redwood City, CA) can be used to risk stratify early-stage estrogen receptor (ER) –positive breast cancer.
- Another strong predictor of outcome in ER-positive disease is proliferation or genomic grade.
- the 70-gene MammaPrint (Agendia, Huntington Beach, CA) microarray assay has shown prognostic significance in ER-positive and ER-negative early-stage node-negative breast cancer.
Parker et al (2009) published microarray data (GEO data set GSE10886)，数据可以比较方便的下载重现整个思路，只需要测定50个基因的表达量即可。
PAM50 classifier usage
The centroids, gene lists, and R code to produce the classification are all available along with the clinical information for the training set on this page: https://genome.unc.edu/pubsup/breastGEO/
Specifically, the R code and supporting data files are here: https://genome.unc.edu/pubsup/breastGEO/PAM50.zip
And the centroids alone are here: https://genome.unc.edu/pubsup/breastGEO/pam50_centroids.txt
In addition, this document provides additional information regarding classification of the PAM50 plus Claudin-low calls https://genome.unc.edu/pubsup/breastGEO/Guide%20to%20Intrinsic%20Subtyping%209-6-10.pdf
Anyone running PAM50 (or any classifier based on relative measurements such as expression) should understand the concepts in this paper: http://www.breast-cancer-research.com/content/pdf/s13058-015-0520-4.pdf
2011年一篇文章 提出了Montreal cohort of 87 patients的30个基因，也可以比较好的区分这些亚型：
这两个基因集的交叉，Of these 30 genes, only 7 of the 30 genes overlapped with the PAM50 (FOXA1, MLPH, ESR1, SLC39A6, NAT1, GRB7 and ERBB2) (Parker et al, 2009)